
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics Inc demonstrated a narrower-than-expected net loss of $1.14 per share in 2Q25, improving on the original estimate of $1.22 per share, indicating effective cost management and operational efficiency. The positive clinical results for OKI-219, which was well-tolerated with no instances of hyperglycemia and only Grade 1 treatment-related adverse events, underscore the potential for successful therapeutic development in an underserved market. This combination of improved financial performance and promising clinical data supports a positive outlook for the company’s future growth prospects.
Bears say
OnKure Therapeutics Inc. is projected to incur a net loss of $4.56 per share for the full year 2025, a slight improvement from the previous estimate of $4.75 per share. The company faces significant risks, including the potential for negative clinical results from its lead asset, OKI-219, and possible delays in advancing its pipeline candidates. Additionally, there are concerns regarding regulatory approval timelines and intense competition, particularly from other mutant-selective PI3Kα inhibitors, which could undermine the company’s market position and future financial performance.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares